Phase l Study – Boltbody™ Immune-Stimulating Antibody Conjugates (ISAC)

Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, Inc., discusses how Bolt is developing drugs to turn cold tumors “hot” to achieve an anti-tumoral activity in unresponsive patients.  They are ahead of their competitors as they have already started the Phase 1 study of BDC-1001 monotherapy for patients with HER2-expressed solid tumors.  He discusses how they are using the Boltbody™ Immune-Stimulating Antibody Conjugates (ISAC) approach to combat cancer and how this technology is shaping the treatment of cancers.

Dr. Randall Schatzman, Ph.D., chief executive officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.